187 related articles for article (PubMed ID: 34564699)
1. Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients.
Blixt L; Bogdanovic G; Buggert M; Gao Y; Hober S; Healy K; Johansson H; Kjellander C; Mravinacova S; Muschiol S; Nilsson P; Palma M; Pin E; Smith CIE; Stromberg O; Sällberg Chen M; Zain R; Hansson L; Österborg A
Leukemia; 2022 Feb; 36(2):476-481. PubMed ID: 34564699
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients.
Del Poeta G; Bomben R; Polesel J; Rossi FM; Pozzo F; Zaina E; Cattarossi I; Varaschin P; Nanni P; Boschian Boschin R; Postorino M; Laureana R; Pasqualone G; Steffan A; Gentile M; Zucchetto A; Gattei V
Hematol Oncol; 2021 Dec; 39(5):712-714. PubMed ID: 34462939
[No Abstract] [Full Text] [Related]
3. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.
Zollner A; Watschinger C; Rössler A; Farcet MR; Penner A; Böhm V; Kiechl SJ; Stampfel G; Hintenberger R; Tilg H; Koch R; Antlanger M; Kreil TR; Kimpel J; Moschen AR
EBioMedicine; 2021 Aug; 70():103539. PubMed ID: 34391087
[TBL] [Abstract][Full Text] [Related]
4. Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients.
Mohn KG; Bredholt G; Zhou F; Madsen A; Onyango TB; Fjelltveit EB; Jalloh SL; Brokstad KA; Cantoni D; Mayora-Neto M; Temperton N; Langeland N; Cox RJ;
PLoS One; 2022; 17(2):e0261979. PubMed ID: 35192617
[TBL] [Abstract][Full Text] [Related]
5. Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic.
Arellano-Llamas AA; Vela-Ojeda J; Hernandez-Caballero A
Curr Oncol Rep; 2022 Feb; 24(2):209-213. PubMed ID: 35061199
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection.
Yang Y; Yang M; Peng Y; Liang Y; Wei J; Xing L; Guo L; Li X; Li J; Wang J; Li M; Xu Z; Zhang M; Wang F; Shi Y; Yuan J; Liu Y
Nat Microbiol; 2022 Mar; 7(3):423-433. PubMed ID: 35132197
[TBL] [Abstract][Full Text] [Related]
7. Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia.
Tadmor T; Benjamini O; Braester A; Rahav G; Rokach L
Leukemia; 2021 Sep; 35(9):2727-2730. PubMed ID: 34376803
[No Abstract] [Full Text] [Related]
8. B careful: Humoral responses and COVID-19 severity.
Fanous H; Guerrero-Pena A; Pillai A
Sci Immunol; 2020 Dec; 5(54):. PubMed ID: 33277373
[TBL] [Abstract][Full Text] [Related]
9. Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report.
Cuneo A; Rigolin GM; Coscia M; Quaresmini G; Scarfò L; Mauro FR; Motta M; Quaglia FM; Trentin L; Ferrario A; Laurenti L; Reda G; Ferrari A; Pietrasanta D; Sportoletti P; Re F; De Paoli L; Foglietta M; Giordano A; Marchetti M; Farina L; Del Poeta G; Varettoni M; Chiurazzi F; Marasca R; Malerba L; Ibatici A; Tisi MC; Stefoni V; Leone M; Baratè C; Olivieri J; Murru R; Gentile M; Sanna A; Gozzetti A; Gattei V; Gottardi D; Derenzini E; Levato L; Orsucci L; Penna G; Chiarenza A; Foà R
Hematol Oncol; 2021 Oct; 39(4):570-574. PubMed ID: 34258787
[No Abstract] [Full Text] [Related]
10. Persistence of Antibody and Cellular Immune Responses in Coronavirus Disease 2019 Patients Over Nine Months After Infection.
Yao L; Wang GL; Shen Y; Wang ZY; Zhan BD; Duan LJ; Lu B; Shi C; Gao YM; Peng HH; Wang GQ; Wang DM; Jiang MD; Cao GP; Ma MJ
J Infect Dis; 2021 Aug; 224(4):586-594. PubMed ID: 33978754
[TBL] [Abstract][Full Text] [Related]
11. T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern.
Cohen H; Rotem S; Elia U; Bilinsky G; Levy I; Chitlaru T; Bar-Haim E
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215940
[TBL] [Abstract][Full Text] [Related]
12. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection.
Wang Z; Muecksch F; Schaefer-Babajew D; Finkin S; Viant C; Gaebler C; Hoffmann HH; Barnes CO; Cipolla M; Ramos V; Oliveira TY; Cho A; Schmidt F; Da Silva J; Bednarski E; Aguado L; Yee J; Daga M; Turroja M; Millard KG; Jankovic M; Gazumyan A; Zhao Z; Rice CM; Bieniasz PD; Caskey M; Hatziioannou T; Nussenzweig MC
Nature; 2021 Jul; 595(7867):426-431. PubMed ID: 34126625
[TBL] [Abstract][Full Text] [Related]
13. Naturally Acquired SARS-CoV-2 Immunity Persists for Up to 11 Months Following Infection.
De Giorgi V; West KA; Henning AN; Chen LN; Holbrook MR; Gross R; Liang J; Postnikova E; Trenbeath J; Pogue S; Scinto T; Alter HJ; Cantilena CC
J Infect Dis; 2021 Oct; 224(8):1294-1304. PubMed ID: 34089610
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
[TBL] [Abstract][Full Text] [Related]
15. Durable SARS-CoV-2 B cell immunity after mild or severe disease.
Ogega CO; Skinner NE; Blair PW; Park HS; Littlefield K; Ganesan A; Dhakal S; Ladiwala P; Antar AA; Ray SC; Betenbaugh MJ; Pekosz A; Klein SL; Manabe YC; Cox AL; Bailey JR
J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33571162
[TBL] [Abstract][Full Text] [Related]
16. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study.
Fendler A; Shepherd STC; Au L; Wilkinson KA; Wu M; Byrne F; Cerrone M; Schmitt AM; Joharatnam-Hogan N; Shum B; Tippu Z; Rzeniewicz K; Boos LA; Harvey R; Carlyle E; Edmonds K; Del Rosario L; Sarker S; Lingard K; Mangwende M; Holt L; Ahmod H; Korteweg J; Foley T; Bazin J; Gordon W; Barber T; Emslie-Henry A; Xie W; Gerard CL; Deng D; Wall EC; Agua-Doce A; Namjou S; Caidan S; Gavrielides M; MacRae JI; Kelly G; Peat K; Kelly D; Murra A; Kelly K; O'Flaherty M; Dowdie L; Ash N; Gronthoud F; Shea RL; Gardner G; Murray D; Kinnaird F; Cui W; Pascual J; Rodney S; Mencel J; Curtis O; Stephenson C; Robinson A; Oza B; Farag S; Leslie I; Rogiers A; Iyengar S; Ethell M; Messiou C; Cunningham D; Chau I; Starling N; Turner N; Welsh L; van As N; Jones RL; Droney J; Banerjee S; Tatham KC; O'Brien M; Harrington K; Bhide S; Okines A; Reid A; Young K; Furness AJS; Pickering L; Swanton C; ; Gandhi S; Gamblin S; Bauer DLV; Kassiotis G; Kumar S; Yousaf N; Jhanji S; Nicholson E; Howell M; Walker S; Wilkinson RJ; Larkin J; Turajlic S;
Nat Cancer; 2021 Dec; 2(12):1305-1320. PubMed ID: 35121899
[TBL] [Abstract][Full Text] [Related]
17. Immune Memory in Mild COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection.
Ansari A; Arya R; Sachan S; Jha SN; Kalia A; Lall A; Sette A; Grifoni A; Weiskopf D; Coshic P; Sharma A; Gupta N
Front Immunol; 2021; 12():636768. PubMed ID: 33777028
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
[TBL] [Abstract][Full Text] [Related]
19. The long road.
Cohen J
Science; 2021 Feb; 371(6531):768-772. PubMed ID: 33602838
[No Abstract] [Full Text] [Related]
20. Biodistribution and serologic response in SARS-CoV-2 induced ARDS: A cohort study.
Schlesinger T; Weißbrich B; Wedekink F; Notz Q; Herrmann J; Krone M; Sitter M; Schmid B; Kredel M; Stumpner J; Dölken L; Wischhusen J; Kranke P; Meybohm P; Lotz C
PLoS One; 2020; 15(11):e0242917. PubMed ID: 33232382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
